Healthcare | October 05, 2021
Amber Implants VCFix spinal system receives breakthrough designation
The first clinical trial is expected to commence in early 2022 both in Europe and the US
The first clinical trial is expected to commence in early 2022 both in Europe and the US
According to IQVIA, US sales of Everolimus (Afinitor) tablets were approximately US $ 675 million in the 12 months ending July 2021
Its store network grew from 144 stores in March 2019 to 236 stores. It has a presence in 23 cities across Maharashtra, Goa and Karnataka, employing more than 4,600 people.
Cardiovascular disease is the leading cause of death in the Asia Pacific, and it's a problem that will only intensify as populations continue to age
The CAC solution cleared by the U.S. FDA analyses already existing non-gated CT scans and quantifies the coronary artery calcium in order to identify, stratify, and facilitate treatment pathways for patients with cardiovascular disease
In terms of volume, the company commands a market share 25 per cent globally for Gliclazide, as per the IQVIA report
Advancement to Phase 3 is a major milestone for SAB’s unique DiversitAb immunotherapy platform that produces fully human polyclonal antibodies without human donors
These modules will act as a guide to doctors and health care workers to deal with post-Covid-19 issues
Ampion is directly administered by inhalation and it allows the drug to directly target and attenuate inflammation in the lungs
New Gibco AAV-MAX Helper Free AAV Production System helps reduce production costs and streamline the transition from research to clinical environments
Subscribe To Our Newsletter & Stay Updated
